Cargando…

Increased Levels of Caspase-1 and IL-1β Among Adults With Persistent Immune Activation After 12 Years of Suppressive Antiretroviral Therapy in the Infectious Diseases Institute HIV Treatment Cohort

BACKGROUND: We sought evidence of activated pyroptosis and the inflammasome pathways among human immunodeficiency virus (HIV)–infected adults after 12 years of suppressive antiretroviral therapy (ART) and persistent immune activation in the Infectious Diseases Institute HIV treatment cohort in Ugand...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabatanzi, Rose, Ssekamatte, Phillip, Castelnuovo, Barbara, Kambugu, Andrew, Nakanjako, Damalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638490/
https://www.ncbi.nlm.nih.gov/pubmed/37953818
http://dx.doi.org/10.1093/ofid/ofad539
_version_ 1785133606247596032
author Nabatanzi, Rose
Ssekamatte, Phillip
Castelnuovo, Barbara
Kambugu, Andrew
Nakanjako, Damalie
author_facet Nabatanzi, Rose
Ssekamatte, Phillip
Castelnuovo, Barbara
Kambugu, Andrew
Nakanjako, Damalie
author_sort Nabatanzi, Rose
collection PubMed
description BACKGROUND: We sought evidence of activated pyroptosis and the inflammasome pathways among human immunodeficiency virus (HIV)–infected adults after 12 years of suppressive antiretroviral therapy (ART) and persistent immune activation in the Infectious Diseases Institute HIV treatment cohort in Uganda. METHODS: In a cross-sectional study, using peripheral blood mononuclear cells of HIV-infected individuals with high and low immune activation (CD4/CD8(+)CD38(+)HLA-DR(+) cells) relative to HIV-negative reference group, caspase-1 expression was measured using flow cytometry and plasma interleukin 18 and interleukin 1β (IL-1β) levels using enzyme-linked immunosorbent assay. RESULTS: There was higher expression of caspase-1 by CD4 T cells of ART-treated individuals with high immune activation relative to those with lower immune activation (P = .04). Similarly, plasma levels of IL-1β were higher among ART-treated individuals with high immune activation levels relative to those with low immune activation levels (P = .009). We observed a low positive correlation between caspase-1 expression by CD4/CD8 T cells and immune activation levels (r  = 0.497 and r  = 0.329, respectively). CONCLUSIONS: Caspase-1 and IL-1β were high among individuals with high immune activation despite 12 years of suppressive ART. There is a need to further understand the role of persistent abortive infection and the latent HIV reservoir characteristics as drivers of persistent activation and inflammation and to subsequently intervene to prevent the complications of chronic immune activation during long-term ART.
format Online
Article
Text
id pubmed-10638490
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106384902023-11-11 Increased Levels of Caspase-1 and IL-1β Among Adults With Persistent Immune Activation After 12 Years of Suppressive Antiretroviral Therapy in the Infectious Diseases Institute HIV Treatment Cohort Nabatanzi, Rose Ssekamatte, Phillip Castelnuovo, Barbara Kambugu, Andrew Nakanjako, Damalie Open Forum Infect Dis Major Article BACKGROUND: We sought evidence of activated pyroptosis and the inflammasome pathways among human immunodeficiency virus (HIV)–infected adults after 12 years of suppressive antiretroviral therapy (ART) and persistent immune activation in the Infectious Diseases Institute HIV treatment cohort in Uganda. METHODS: In a cross-sectional study, using peripheral blood mononuclear cells of HIV-infected individuals with high and low immune activation (CD4/CD8(+)CD38(+)HLA-DR(+) cells) relative to HIV-negative reference group, caspase-1 expression was measured using flow cytometry and plasma interleukin 18 and interleukin 1β (IL-1β) levels using enzyme-linked immunosorbent assay. RESULTS: There was higher expression of caspase-1 by CD4 T cells of ART-treated individuals with high immune activation relative to those with lower immune activation (P = .04). Similarly, plasma levels of IL-1β were higher among ART-treated individuals with high immune activation levels relative to those with low immune activation levels (P = .009). We observed a low positive correlation between caspase-1 expression by CD4/CD8 T cells and immune activation levels (r  = 0.497 and r  = 0.329, respectively). CONCLUSIONS: Caspase-1 and IL-1β were high among individuals with high immune activation despite 12 years of suppressive ART. There is a need to further understand the role of persistent abortive infection and the latent HIV reservoir characteristics as drivers of persistent activation and inflammation and to subsequently intervene to prevent the complications of chronic immune activation during long-term ART. Oxford University Press 2023-11-07 /pmc/articles/PMC10638490/ /pubmed/37953818 http://dx.doi.org/10.1093/ofid/ofad539 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Major Article
Nabatanzi, Rose
Ssekamatte, Phillip
Castelnuovo, Barbara
Kambugu, Andrew
Nakanjako, Damalie
Increased Levels of Caspase-1 and IL-1β Among Adults With Persistent Immune Activation After 12 Years of Suppressive Antiretroviral Therapy in the Infectious Diseases Institute HIV Treatment Cohort
title Increased Levels of Caspase-1 and IL-1β Among Adults With Persistent Immune Activation After 12 Years of Suppressive Antiretroviral Therapy in the Infectious Diseases Institute HIV Treatment Cohort
title_full Increased Levels of Caspase-1 and IL-1β Among Adults With Persistent Immune Activation After 12 Years of Suppressive Antiretroviral Therapy in the Infectious Diseases Institute HIV Treatment Cohort
title_fullStr Increased Levels of Caspase-1 and IL-1β Among Adults With Persistent Immune Activation After 12 Years of Suppressive Antiretroviral Therapy in the Infectious Diseases Institute HIV Treatment Cohort
title_full_unstemmed Increased Levels of Caspase-1 and IL-1β Among Adults With Persistent Immune Activation After 12 Years of Suppressive Antiretroviral Therapy in the Infectious Diseases Institute HIV Treatment Cohort
title_short Increased Levels of Caspase-1 and IL-1β Among Adults With Persistent Immune Activation After 12 Years of Suppressive Antiretroviral Therapy in the Infectious Diseases Institute HIV Treatment Cohort
title_sort increased levels of caspase-1 and il-1β among adults with persistent immune activation after 12 years of suppressive antiretroviral therapy in the infectious diseases institute hiv treatment cohort
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638490/
https://www.ncbi.nlm.nih.gov/pubmed/37953818
http://dx.doi.org/10.1093/ofid/ofad539
work_keys_str_mv AT nabatanzirose increasedlevelsofcaspase1andil1bamongadultswithpersistentimmuneactivationafter12yearsofsuppressiveantiretroviraltherapyintheinfectiousdiseasesinstitutehivtreatmentcohort
AT ssekamattephillip increasedlevelsofcaspase1andil1bamongadultswithpersistentimmuneactivationafter12yearsofsuppressiveantiretroviraltherapyintheinfectiousdiseasesinstitutehivtreatmentcohort
AT castelnuovobarbara increasedlevelsofcaspase1andil1bamongadultswithpersistentimmuneactivationafter12yearsofsuppressiveantiretroviraltherapyintheinfectiousdiseasesinstitutehivtreatmentcohort
AT kambuguandrew increasedlevelsofcaspase1andil1bamongadultswithpersistentimmuneactivationafter12yearsofsuppressiveantiretroviraltherapyintheinfectiousdiseasesinstitutehivtreatmentcohort
AT nakanjakodamalie increasedlevelsofcaspase1andil1bamongadultswithpersistentimmuneactivationafter12yearsofsuppressiveantiretroviraltherapyintheinfectiousdiseasesinstitutehivtreatmentcohort